Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.

Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, Ram R, Raanani P, Ofran Y, Wolach O.

Ann Hematol. 2019 Sep 11. doi: 10.1007/s00277-019-03795-8. [Epub ahead of print]

PMID:
31512015
2.

Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study.

Shargian-Alon L, Gafter-Gvili A, Ben-Zvi H, Wolach O, Yeshurun M, Raanani P, Yahav D.

Leuk Lymphoma. 2019 Apr 24:1-6. doi: 10.1080/10428194.2019.1599113. [Epub ahead of print]

PMID:
31014145
3.

Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation.

Pasvolsky O, Morelli O, Rozovski U, Vaturi M, Wolach O, Amitai I, Vaxman I, Ratzon R, Yeshurun M, Kornowski R, Iakobishvilli Z, Raanani P.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e343-e348. doi: 10.1016/j.clml.2019.03.007. Epub 2019 Mar 11.

PMID:
30948329
4.

Autologous hematopoietic cell transplantation for AML in first remission - An abandoned practice or promising approach?

Yeshurun M, Wolach O.

Semin Hematol. 2019 Apr;56(2):139-146. doi: 10.1053/j.seminhematol.2019.01.001. Epub 2019 Feb 14. Review.

PMID:
30926090
5.

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V.

Blood Adv. 2019 Feb 26;3(4):670-680. doi: 10.1182/bloodadvances.2018027003.

6.

Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation - a single-center experience.

Shargian-Alon L, Yahav D, Rozovski U, Dovrat S, Amitai I, Sela-Navon M, Pasvolsky O, Raanani P, Yeshurun M.

Leuk Lymphoma. 2019 Feb 18:1-7. doi: 10.1080/10428194.2019.1576869. [Epub ahead of print]

PMID:
30773083
7.

Impaired lymphocyte reconstitution after autologous transplant is associated with apoptosis of CD8+ T cells and adverse clinical outcome.

Rozovski U, Naparstek E, Frank S, Fourman A, Zigman-Hoffman E, Bleiberg M, Yeshurun M, Trestman S, Tartakovsky B.

Leuk Lymphoma. 2019 Jan 18:1-7. doi: 10.1080/10428194.2018.1563696. [Epub ahead of print]

PMID:
30656985
8.

Dysfunctional endothelial progenitor cells in patients with Hodgkin's lymphoma in complete remission.

Wiessman M, Leshem D, Yeshurun M, Yavin H, Iakobishvilli Z, Raanani P, Kornowski R, Lev EI, Vaturi M.

Cancer Med. 2019 Jan;8(1):305-310. doi: 10.1002/cam4.1914. Epub 2018 Dec 13.

9.

Immune Mediated Cerebellar Ataxia: An Unknown Manifestation of Graft-versus-Host Disease.

Shargian-Alon L, Raanani P, Rozovski U, Siegal T, Yust-Katz S, Yeshurun M.

Acta Haematol. 2019;141(1):19-22. doi: 10.1159/000494423. Epub 2018 Nov 15.

PMID:
30439710
10.

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.

Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M.

JAMA Oncol. 2018 Sep 1;4(9):1245-1253. doi: 10.1001/jamaoncol.2018.2091.

11.

When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission?

Yeshurun M, Wolach O.

Curr Opin Hematol. 2018 Mar;25(2):75-80. doi: 10.1097/MOH.0000000000000410. Review.

PMID:
29283907
12.

Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study.

Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O, Wolach O, Lahav M, Gurion R, Magen H, Vidal L, Herscovici C, Peck A, Moshe M, Sela-Navon M, Naparstek E, Raanani P, Rozovski U.

Clin Microbiol Infect. 2018 Jul;24(7):749-754. doi: 10.1016/j.cmi.2017.11.019. Epub 2017 Dec 6.

13.

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.

Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A.

J Hematol Oncol. 2017 Jan 24;10(1):31. doi: 10.1186/s13045-016-0389-4.

14.

Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.

Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L, Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R.

Ann Hematol. 2017 Feb;96(2):271-278. doi: 10.1007/s00277-016-2882-9. Epub 2016 Dec 30.

PMID:
28039512
15.

High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia.

Shacham-Abulafia A, Itchaki G, Yeshurun M, Paul M, Peck A, Leader A, Shpilberg O, Ram R, Raanani P.

Acta Haematol. 2016;135(1):55-64. doi: 10.1159/000437131. Epub 2015 Oct 8.

PMID:
26443995
16.

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.

Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, Israeli M, Levy-Assaraf M, Gruenewald T, Mechoulam R, Raanani P, Ram R.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5. doi: 10.1016/j.bbmt.2015.05.018. Epub 2015 May 30.

17.

Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation.

Cohen L, Yeshurun M, Shpilberg O, Ram R.

Transpl Infect Dis. 2015 Aug;17(4):510-7. doi: 10.1111/tid.12398. Epub 2015 Jun 18.

PMID:
25940504
18.

High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?

Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P.

Hematol Oncol. 2016 Mar;34(1):28-35. doi: 10.1002/hon.2191. Epub 2015 Feb 17.

PMID:
25689584
19.

Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis.

Vaxman I, Ram R, Gafter-Gvili A, Vidal L, Yeshurun M, Lahav M, Shpilberg O.

Bone Marrow Transplant. 2015 May;50(5):706-14. doi: 10.1038/bmt.2014.325. Epub 2015 Feb 9. Review.

PMID:
25665042
20.

First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.

Muchtar E, Ram R, Raanani P, Yeshurun M, Oniashvili N, Shpilberg O, Magen H.

Leuk Res. 2014 Dec;38(12):1401-6. doi: 10.1016/j.leukres.2014.06.024. Epub 2014 Jul 10.

PMID:
25060304
21.

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.

Ram R, Herscovici C, Dahan D, Israeli M, Dreyer J, Peck A, Shpilberg O, Yeshurun M.

Leuk Res. 2014 Aug;38(8):913-7. doi: 10.1016/j.leukres.2014.05.020. Epub 2014 Jun 4.

PMID:
24939215
22.

Myeloma in scar tissue--an underreported phenomenon or an emerging entity in the novel agents' era? A single center series.

Muchtar E, Raanani P, Yeshurun M, Shpilberg O, Magen-Nativ H.

Acta Haematol. 2014;132(1):39-44. doi: 10.1159/000354830. Epub 2014 Jan 10.

PMID:
24434613
23.

Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis.

Ram R, Yeshurun M, Vidal L, Shpilberg O, Gafter-Gvili A.

Leuk Res. 2014 Mar;38(3):352-60. doi: 10.1016/j.leukres.2013.12.012. Epub 2013 Dec 25. Review.

PMID:
24418750
24.

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.

Cancer. 2014 Mar 15;120(6):855-63. doi: 10.1002/cncr.28498. Epub 2013 Dec 10.

25.

Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.

Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P.

Am J Hematol. 2014 Mar;89(3):243-8. doi: 10.1002/ajh.23622.

26.

Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Varda-Bloom N, Rheingold L, Yeshurun M, Bielorai B, Toren A, Zuckerman T, Nagler A, Or R.

Am J Blood Res. 2013 Aug 19;3(3):225-38. eCollection 2013.

27.

The role of ¹⁸F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia.

Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, Yeshurun M, Tadmor B, Leibovici L, Shpilberg O, Groshar D.

Leuk Res. 2013 Sep;37(9):1057-62. doi: 10.1016/j.leukres.2013.06.025. Epub 2013 Jul 10.

PMID:
23849986
28.

Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation.

Ram R, Yeshurun M, Farbman L, Herscovici C, Shpilberg O, Paul M.

J Infect. 2013 Sep;67(3):194-8. doi: 10.1016/j.jinf.2013.05.005. Epub 2013 May 23.

PMID:
23707844
29.

Trends and challenges in searching for HLA-matched unrelated donors in Israel.

Israeli M, Yeshurun M, Stein J, Ram R, Shpilberg O, Levi CL, Klein T.

Hum Immunol. 2013 Aug;74(8):942-5. doi: 10.1016/j.humimm.2013.04.012. Epub 2013 Apr 22.

PMID:
23619470
30.

Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay.

Israeli M, Klein T, Herscovici C, Ram R, Shpilberg O, Sredni B, Yeshurun M.

Clin Exp Immunol. 2013 Jun;172(3):475-82. doi: 10.1111/cei.12072.

31.

Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.

Ram R, Magen-Nativ H, Vidal L, Herscovici C, Peck A, Raanani P, Shpilberg O, Yeshurun M.

Clin Transplant. 2012 Sep-Oct;26(5):E549-54. doi: 10.1111/ctr.12018.

PMID:
23061765
32.

Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients.

Ram R, Farbman L, Leibovici L, Raanani P, Yeshurun M, Vidal L, Gafter-Gvili A, Peck A, Shpilberg O, Paul M.

Int J Antimicrob Agents. 2012 Aug;40(2):123-6. doi: 10.1016/j.ijantimicag.2012.05.001. Epub 2012 Jun 22.

PMID:
22727772
33.

Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.

Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, Offen D.

Exp Neurol. 2012 Apr;234(2):417-27. doi: 10.1016/j.expneurol.2011.12.045. Epub 2012 Jan 20.

PMID:
22285250
34.

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A.

Cancer. 2012 Oct 1;118(19):4706-14. doi: 10.1002/cncr.27418. Epub 2012 Jan 17.

35.

Acute promyelocytic leukemia with a smoldering course associated with therapy-related myelodysplastic syndrome.

Wolach O, Yeshurun M, Amariglio N, Shpilberg O, Raanani P.

Acta Haematol. 2011;126(3):152-6. doi: 10.1159/000328997. Epub 2011 Jul 14.

PMID:
21757888
36.

Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience.

Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A.

Infection. 2010 Jun;38(3):211-5. doi: 10.1007/s15010-010-0023-2. Epub 2010 Apr 28.

PMID:
20425134
37.

Antiviral prophylaxis in haematological patients: systematic review and meta-analysis.

Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M, Leibovici L, Paul M.

Eur J Cancer. 2009 Dec;45(18):3131-48. doi: 10.1016/j.ejca.2009.08.010. Epub 2009 Sep 30. Review.

PMID:
19796930
38.

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.

Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O.

Haematologica. 2010 Feb;95(2):303-10. doi: 10.3324/haematol.2009.010611. Epub 2009 Sep 22.

39.

Surveillance of infectious complications in hemato-oncological patients.

Ram R, Gafter-Gvili A, Raanani P, Yeshurun M, Shpilberg O, Dreyer J, Peck A, Leibovici L, Paul M.

Isr Med Assoc J. 2009 Mar;11(3):133-7.

40.

Total therapy-based treatment for multiple myeloma--a single center experience.

Magen-Nativ H, Ram R, Yeshurun M, Gafter-Gvili A, Raanani P, Shpilberg O.

Ann Hematol. 2010 Jan;89(1):53-9. doi: 10.1007/s00277-009-0767-x. Epub 2009 Jun 6.

PMID:
19504094
41.

Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, Shpilberg O, Raanani P.

Haematologica. 2009 May;94(5):712-9. doi: 10.3324/haematol.2008.002170. Epub 2009 Mar 31. Review.

42.

ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis.

Gafter-Gvili A, Ram R, Gurion R, Paul M, Yeshurun M, Raanani P, Shpilberg O.

Acta Haematol. 2008;120(4):237-43. doi: 10.1159/000203403. Epub 2009 Feb 25. Review.

PMID:
19246887
43.

Prophylaxis regimens for GVHD: systematic review and meta-analysis.

Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O.

Bone Marrow Transplant. 2009 Apr;43(8):643-53. doi: 10.1038/bmt.2008.373. Epub 2008 Nov 10. Review.

PMID:
18997826
44.

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M.

J Clin Oncol. 2007 Dec 1;25(34):5471-89. Epub 2007 Oct 1. Review.

PMID:
17909198
45.

Combined increased and decreased skeletal uptake of F-18 FDG.

Goshen E, Davidson T, Yeshurun M, Zwas ST.

Clin Nucl Med. 2006 Sep;31(9):520-2.

PMID:
16921273
46.

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A.

Leukemia. 2006 Feb;20(2):322-8.

PMID:
16307018
47.

A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors.

Robin M, Guardiola P, Devergie A, Yeshurun M, Shapiro S, Esperou H, Ribaud P, Rocha V, Gluckman E, Socié G.

Leukemia. 2005 Sep;19(9):1613-20.

PMID:
15990868
48.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.

Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A.

Leukemia. 2005 Jan;19(1):7-12.

PMID:
15526016
49.

A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.

Laporte JP, Yeshurun M, Fouillard L, Labopin M, Cailliot C, Lesage S, Isnard F, Najman A, Gorin NC.

Leukemia. 2004 Oct;18(10):1717-21.

PMID:
15295607
50.

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.

Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A.

Biol Blood Marrow Transplant. 2004 Jul;10(7):484-93.

Supplemental Content

Loading ...
Support Center